Tier 3 — preclinical

Safety assessment of nicotinamide riboside, a form of vitamin B 3

Conze DB, Crespo-Barreto J, Kruger CL
Human & experimental toxicology 2016 35; 11; 1149-1160

Bibliography

PubMed
PMID 26791540
DOI
10.1177/0960327115626254
Funding
Funding details are not specified in the accessible publication information.
Competing interests
A complete competing-interest declaration is not specified in the accessible publication information.

Study snapshot

DesignPreclinical animal study with supporting assays as applicable
ModelBacterial and cellular assays and rats
SampleGenotoxicity assays and rat toxicology cohorts
InterventionNR chloride at several doses; 300–3000 mg/kg/day in the repeat-dose study
DurationAcute, 14-day and 90-day protocols
EndpointsModel-specific physiological outcomes; Biochemical or functional measures reported in the study

What the study showed, in plain terms

The test battery did not identify genotoxicity; high-dose repeat exposure produced organ-related toxicity findings in rats.

Key findings

The repeat-dose rat NOAEL was 300 mg/kg/day and LOAEL 1000 mg/kg/day.

What this study can and cannot tell us

Nonclinical NOAEL and LOAEL values are not human supplement doses. Safety conclusions depend on route, formulation, exposure and population.

Related papers in the corpus

Tier 3
Ototoxic Effect of Nicotinamide Riboside
Ivanov SA et al. · Bulletin of experimental biology and medicine · 2024
Tier 3
Preclinical safety assessments of nicotinamide riboside hydrogen malate
Margitta Dziwenka et al. · Toxicology Research and Application · 2022
Tier 3
Safety Assessment of High-Purity, Synthetic Nicotinamide Riboside (NR-E) in a 90-Day Repeated Dose Oral Toxicity Study, With a 28-Day Recovery Arm
Marinescu AG et al. · International journal of toxicology · 2020
Tier 4
Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC
Turck D et al. · EFSA journal. European Food Safety Authority · 2019

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology